Gerinnungsmonitoring – praktisches Management

Schlüsselwörter

Antikoagulanzien - Laborbestimmungen - Therapieüberwachungsmöglichkeiten

Keywords

Anticoagulants - Assays - monitoring options

• Literatur

• 1 Asmis LM, Alberio L, Angelillo-Scherrer A et al. Rivaroxaban: quantification by anti FXa assay and influence on coagulation tests. A study in 9 Swiss laboratories. Thromb Res 2012; 129: 492-498
• 2 Bates SM, Weitz JI. Coagulation assays. Circulation 2005; 112: e53-60
• 3 Douxfils J, Mullier F, Robert S et al. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012; 107: 985-997
• 4 Frost C, Yu Z, Moore K et al. Apixaban an oral direct factor Xa inhibitor: multiple-dose safety. Pharmacokinetics, and pharmacodynamics in healthy subjects.XXIst ISTH Congress August 2007 (abstract). J Thromb Haemost 2007; 5 (Suppl. 02) P-M 664
• 5 Hattersley PG. Activated coagulation time of whole blood. JAMA 1966; 196: 436-440
• 6 Holbrock A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy. American College of Chest Physicans. 9th ed. Chest 2012; 141: 152S-184S
• 7 Lewandrowski EL, van Cott EM, Gregory K et al. Clinical evaluation of the i-STAT kaolin activated clotting time (ACT) test in different clinical settings in a large academic urban medical center: comparison with the Medtronic ACT Plus. Am J Clin Pathol 2011; 135: 741-748
• 8 Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838-1843
• 9 Lewis BE, Wallis DE, Leya F et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163: 1849-1856
• 10 Nieuwenhuis HK, Albada J, Banga JD et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991; 78: 2337-2343
• 11 Nowak G. The ecarin clotting time, a universal method to quantifiy direct thrombin inhibitors. Pathophysiol Haemost Thromb 2003; 33: 173-183
• 12 Paolucci F, Frasa H, van Aarle F et al. Two sensitive and rapid chromogenic assays of fondaparinux sodium (Arixtra) in human plasma and other biological matrices. Clin Lab 2003; 49: 451-460
• 13 Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med 2011; 49: 761-772
• 14 Samama MM, Contant G, Spiro TE et al. Rivaroxaban antifactor Xa chromogenic assay field trial laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012; 107: 379-387
• 15 Schinzel H. Antithrombotika und Fibrinolysetherapie. In Internistische Therapie Wolff. Weihrauch 2012. Kapitel 10, 2013: 289-344
• 16 Spannagl M, Bauersachs R, Debus ES et al. Patienten unter Therapie mit Dabigatran-Periopertives Management und Interpretation von Gerinnungstesten. Haemostaseologie 2012; 32: 294-305
• 17 Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23: 138-143